Risperdal Gynecomastia Lawsuits Rise To Over 1,000 Claims Contending Anti-Psychoitc Drug Caused Enlarged Breasts in Young Men Reports Wright & Schulte LLC

Print

Johnson & Johnson Faces Mounting Risperdal Gynecomastia Lawsuits Alleging It’s Subsidiary, Janssen Pharmaceuticals Failed To Warn Doctors and Their Patients of the Risks of Enlarged Breasts in Young Men.

risperdal-gynecomastia-lawsuits-Wright-and-Schulte-LLCRisperdal lawsuit complaints continue to move forward in a mass tort program in the Philadelphia Court of Common Pleas, reports Wright & Schulte LLC. The Pennsylvania state court’s master list indicates that the number of Risperdal lawsuits filed have increased to 1,042 complaints as of November 17, 2014. The Risperdal gynecomastia lawsuits have been centralized in the Court of Common Pleas and assigned to Judge Arnold New. The Risperdal lawsuits are filed on behalf of boys and young men who allege that they developed gynecomastia (abnormal growth of breast tissue) and other serious side-effects due to taking the antipsychotic drug. The Risperdal lawsuits further allege that some plaintiffs were forced to undergo liposuction or mastectomies to remove the excess breast tissue. The Risperdal lawsuit complaints contend that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc., failed to warn doctors and their patients about the risks of abnormal breast growth and other health complications linked with Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)

Wright & Schulte continues to offer free legal consultations to males who believe they have developed gynecomastia after taking Risperdal. You can contact one of the firms experienced product liability attorneys by calling 1-800-399-0795 or visit www.yourlegalhelp.com for more information on this and other drug side-effects.

The U.S. Food and Drug Administration (FDA) approved Risperdal as an atypical antipsychotic drug to treat schizophrenia and bipolar disorder, and irritability in autistic children and adolescents. Janssen Pharmaceuticals Inc., however, began marketing Risperdal in 2002 for use unapproved by the FDA to treat agitation associated in elderly non-schizophrenic dementia patients. Janssen also marketed the medication for unapproved use to treat irritability in autistic children and adolescents. The FDA did not approve the drug for use in children for any purpose until late 2006. The FDA repeatedly sent warning letters to Janssen about its “misleading marketing messages” to physicians. Janssen’s marketing tactics came under investigation by the U.S. Department of Justice, which later brought criminal charges against the company. In November 2013, the DOJ announced a guilty plea settlement which involved Johnson & Johnson and Janssen paying a total of $2.2 billion to resolve civil and criminal investigations regarding the prescriptions drugs Risperdal, Invega and Natrecor. According to the DOJ, Janssen specifically pleaded guilty and agreed to pay over $1.6 billion to resolve allegations of misbranding and filing false claims for Risperdal.
[justice.gov/opa/pr/2013/November/13-ag-1170.html, November 4, 2013] [fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]

Court records indicate that in addition to the Risperdal mass litigation in Pennsylvania state court, Risperdal gynecomastia lawsuits are also being filed in federal courts. For instance, one Risperdal lawsuit complaint was filed against Janssen Pharmaceuticals Inc. and Johnson & Johnson in U.S. District Court, Southern District of California on behalf of a California man who alleges he developed gynecomastia and other health issuesafter using Risperdal. According to the Risperdal complaint, the California man was about six years old in November 1997 when he began to use Risperdal for behavioral and psychological issues that he had first began experiencing in 1996. The Risperdal drug lawsuit maintains that the plaintiff continued to use the antipsychotic medication until approximately April 2001, about one month before his 10th birthday. The Rispderal complaint alleges that as a result of using Risperdal from 1997 to 2001, the plaintiff experienced serious side effects that included significant weight gain, enlarged nipples and development of large breasts. Additionally, the lawsuit alleges that the plaintiff began experiencing increased aggression, acting out and other emotional and behavioral problems after discontinuing use of the drug around April 2001. The lawsuit purports that the defendants knew that the FDA had not approved Risperdal for use in young children but they promoted this off-label use anyway. (3:14-cv-00106).

Court records indicate that the first Risperdal bellwether trial scheduled for November 3 has been postponed, and the second bellwether trial was scheduled to begin in January 2015. A case selected for a bellwether trial is representative of a larger group of lawsuits that have common issues. The outcome of bellwether trials act as an indicator of what is likely to happen in similar cases tried in the future.(In Re: Risperdal Litigation, Case Number 100300296)

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377
1-800-399-0795
www.yourlegalhelp.com

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.